Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mirxes Holding Company Limited ( (HK:2629) ) has issued an announcement.
Mirxes Holding Company Limited has entered into a memorandum of understanding with Walvax Biotechnology Co., Ltd. to form a strategic partnership aimed at creating an RNA-centric preventive and precision medicine platform. This collaboration will leverage Mirxes’ RNA diagnostic technologies and Walvax’s mRNA vaccine expertise to establish a research center in Singapore, expedite clinical trials, and enhance sales and distribution in the ASEAN region, marking a significant transition for Mirxes towards preventive medicine.
More about Mirxes Holding Company Limited
Mirxes Holding Company Limited is a company incorporated in the Cayman Islands, focusing on advanced RNA diagnostic technologies and preventive and precision medicine. It has a proprietary Asian-centric disease RNA database and manufacturing capabilities in ASEAN, including a nucleic acid assay and reagent manufacturing plant.
Average Trading Volume: 1,723,342
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$15.76B
For detailed information about 2629 stock, go to TipRanks’ Stock Analysis page.